Journal of Shanghai Jiao Tong University (Medical Science) ›› 2023, Vol. 43 ›› Issue (2): 188-193.doi: 10.3969/j.issn.1674-8115.2023.02.007
• Clinical research • Previous Articles
SHI Cuicui(), ZHANG Jie, HUANG Heming, SANG Yuer(
), LI Guangming(
)
Received:
2022-09-09
Accepted:
2023-02-09
Online:
2023-02-28
Published:
2023-02-28
Contact:
SANG Yuer,LI Guangming
E-mail:shicuicui2005@126.com;sangyuer@xinhuamed.com.cn;ligm68@126.com
Supported by:
CLC Number:
SHI Cuicui, ZHANG Jie, HUANG Heming, SANG Yuer, LI Guangming. Clinical analysis of insulin resistance in liver cirrhosis patients[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(2): 188-193.
Item | IR ≤ 1.64 (n=117) | IR > 1.64 (n=91) | P value |
---|---|---|---|
Age/year | 63.23±12.38 | 61.48±11.11 | 0.290 |
BMI/(kg·m-2) | 22.05±3.50 | 25.64±3.65 | 0.000 |
Male/n (%) | 74 (63.25) | 45 (49.45) | 0.049 |
Smoke/n (%) | 42 (35.90) | 31 (34.07) | 0.880 |
Alcohol/n (%) | 29 (24.79) | 22 (24.18) | >0.990 |
T2DM/n (%) | 30 (25.64) | 44 (48.35) | 0.001 |
Hypertension/n (%) | 28 (23.93) | 29 (31.87) | 0.210 |
Child-Pugh grade | |||
Child-Pugh A/n(%) | 47 (40.17) | 49 (53.85) | 0.070 |
Child-Pugh B /n(%) | 43 (36.75) | 32 (35.16) | 0.880 |
Child-Pugh C/n(%) | 27 (23.08) | 10 (10.99) | 0.028 |
Child-Pugh score | 7.63±2.20 | 6.93±1.99 | 0.020 |
FBG/(mmol·L-1) | 5.44±1.71 | 7.58±3.24 | 0.000 |
HbA1c/% | 5.43±1.02 | 6.54±2.31 | 0.000 |
Fasting insulin/(mIU·L-1) | 4.06±1.87 | 12.32±8.39 | 0.000 |
HOMA-IR | 0.94±0.39 | 4.25±4.51 | 0.000 |
Complication | |||
EVB/n(%) | 51 (43.59) | 40 (43.96) | >0.990 |
Ascites/n(%) | 78 (66.67) | 33 (36.26) | 0.000 |
HE/n(%) | 7 (5.98) | 5 (5.49) | >0.990 |
Tab 1 Comparison of basic information between the groups with and without insulin resistance
Item | IR ≤ 1.64 (n=117) | IR > 1.64 (n=91) | P value |
---|---|---|---|
Age/year | 63.23±12.38 | 61.48±11.11 | 0.290 |
BMI/(kg·m-2) | 22.05±3.50 | 25.64±3.65 | 0.000 |
Male/n (%) | 74 (63.25) | 45 (49.45) | 0.049 |
Smoke/n (%) | 42 (35.90) | 31 (34.07) | 0.880 |
Alcohol/n (%) | 29 (24.79) | 22 (24.18) | >0.990 |
T2DM/n (%) | 30 (25.64) | 44 (48.35) | 0.001 |
Hypertension/n (%) | 28 (23.93) | 29 (31.87) | 0.210 |
Child-Pugh grade | |||
Child-Pugh A/n(%) | 47 (40.17) | 49 (53.85) | 0.070 |
Child-Pugh B /n(%) | 43 (36.75) | 32 (35.16) | 0.880 |
Child-Pugh C/n(%) | 27 (23.08) | 10 (10.99) | 0.028 |
Child-Pugh score | 7.63±2.20 | 6.93±1.99 | 0.020 |
FBG/(mmol·L-1) | 5.44±1.71 | 7.58±3.24 | 0.000 |
HbA1c/% | 5.43±1.02 | 6.54±2.31 | 0.000 |
Fasting insulin/(mIU·L-1) | 4.06±1.87 | 12.32±8.39 | 0.000 |
HOMA-IR | 0.94±0.39 | 4.25±4.51 | 0.000 |
Complication | |||
EVB/n(%) | 51 (43.59) | 40 (43.96) | >0.990 |
Ascites/n(%) | 78 (66.67) | 33 (36.26) | 0.000 |
HE/n(%) | 7 (5.98) | 5 (5.49) | >0.990 |
Item | Child-Pugh A (n=162) | Child-Pugh B (n=148) | Child-Pugh C (n=66) | P value |
---|---|---|---|---|
FBG/(mmol·L-1) | 6.59±2.82 | 6.79±2.88 | 4.98±1.26 | 0.002 |
HbA1c/% | 5.98±1.41 | 5.69±1.17 | 5.45±2.27 | 0.350 |
Fasting insulin/(mIU·L-1) | 9.04±8.36 | 6.49±5.26 | 5.62±5.75 | 0.010 |
HOMA-IR | 3.02±4.47 | 2.01±2.11 | 1.54±1.68 | 0.038 |
Tab 2 Comparison of glucose metabolism indexes of liver cirrhosis patients with different Child-Pugh grades
Item | Child-Pugh A (n=162) | Child-Pugh B (n=148) | Child-Pugh C (n=66) | P value |
---|---|---|---|---|
FBG/(mmol·L-1) | 6.59±2.82 | 6.79±2.88 | 4.98±1.26 | 0.002 |
HbA1c/% | 5.98±1.41 | 5.69±1.17 | 5.45±2.27 | 0.350 |
Fasting insulin/(mIU·L-1) | 9.04±8.36 | 6.49±5.26 | 5.62±5.75 | 0.010 |
HOMA-IR | 3.02±4.47 | 2.01±2.11 | 1.54±1.68 | 0.038 |
Item | Cryptogenic cirrhosis (n=71) | Cirrhosis of the other etiologies (n=305) | P value |
---|---|---|---|
FBG/(mmol·L-1) | 6.47±2.69 | 6.22±2.57 | 0.464 |
HbA1c/% | 5.95±2.28 | 5.73±1.29 | 0.287 |
Fasting insulin/(mIU·L-1) | 6.69±5.66 | 7.95±7.34 | 0.277 |
HOMA-IR | 2.25±3.09 | 2.43±3.51 | 0.746 |
Tab 3 Comparison of glucose metabolism indexes between patients with cryptogenic cirrhosis and those with cirrhosis of other etiologies
Item | Cryptogenic cirrhosis (n=71) | Cirrhosis of the other etiologies (n=305) | P value |
---|---|---|---|
FBG/(mmol·L-1) | 6.47±2.69 | 6.22±2.57 | 0.464 |
HbA1c/% | 5.95±2.28 | 5.73±1.29 | 0.287 |
Fasting insulin/(mIU·L-1) | 6.69±5.66 | 7.95±7.34 | 0.277 |
HOMA-IR | 2.25±3.09 | 2.43±3.51 | 0.746 |
1 | CHAO L T, WU C F, SUNG F Y, et al. Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort[J]. Carcinogenesis, 2011, 32(6): 876-881. |
2 | SINGAL A K, AYOOLA A E. Prevalence and factors affecting occurrence of type 2 diabetes mellitus in Saudi patients with chronic liver disease[J]. Saudi J Gastroenterol, 2008, 14(3): 118-121. |
3 | HUNG C H, WANG J H, HU T H, et al. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection[J]. World J Gastroenterol, 2010, 16(18): 2265-2271. |
4 | PANG Y, KARTSONAKI C, TURNBULL I, et al. Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: a prospective study of 0.5 million people[J]. Hepatology, 2018, 68(4): 1308-1318. |
5 | LIU T L, TROGDON J, WEINBERGER M, et al. Diabetes is associated with clinical decompensation events in patients with cirrhosis[J]. Dig Dis Sci, 2016, 61(11): 3335-3345. |
6 | ANTY R, ANTY R, IANNELLI A, et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients[J]. Aliment Pharmacol Ther, 2010, 32(11/12): 1315-1322. |
7 | BHAGAT V, MINDIKOGLU A L, NUDO C G, et al. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease[J]. Liver Transpl, 2009, 15(12): 1814-1820. |
8 | PETERSEN M C, SHULMAN G I. Mechanisms of insulin action and insulin resistance[J]. Physiol Rev, 2018, 98(4): 2133-2223. |
9 | ESLAM M, SANYAL A J, GEORGE J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014.e1. |
10 | KITADE H, CHEN G, NI Y, et al. Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments[J]. Nutrients, 2017, 9(4): E387. |
11 | 孙志梅, 齐亚娟. 胰岛素信号通路与胰岛素抵抗[J]. 世界最新医学信息文摘, 2019, 19(52): 62-63. |
SUN Z M, QI Y J.Insulin signaling pathway and insulin resistance[J].World's Latest Medical Information Digest, 2019, 19(52): 62-63. | |
12 | HARDEEP S D, NAVIDA B, DEVINDER S M.Prevalence of insulin resistance in cirrhosis of liver[J]. Int J Adv Med, 2018, 5(2): 375. |
13 | GORAL V, ATALAY R, KUCUKONER M. Insulin resistance in liver cirrhosis[J]. Hepatogastroenterology, 2010, 57(98): 309-315. |
14 | YAGMUR E, WEISKIRCHEN R, GRESSNER A M, et al. Insulin resistance in liver cirrhosis is not associated with circulating retinol-binding protein 4[J]. Diabetes Care, 2007, 30(5): 1168-1172. |
15 | GHARAVI A, HAJAGHA M A, ZIAEE A, et al. Investigation of insulin resistance in patients with liver cirrhosis and its relationship with severity of disease[J].J Qazvin Univ Med Sci, 2008, 12(1): 27-34. |
16 | 中华医学会糖尿病学分会胰岛素抵抗学组(筹). 胰岛素抵抗评估方法和应用的专家指导意见[J]. 中华糖尿病杂志, 2018, 10(6): 377-385. |
Insulin Resistance Group of Diabetics Branch of Chinese Medical Association. Expert guidance on methods and application of insulin resistance assessment[J].Chinese Journal of Diabetes,2018,10(6):377-385. | |
17 | PETTA S, CAMMÀ C, DI MARCO V, et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection[J]. Liver Int, 2011, 31(4): 507-515. |
18 | GUO C H, SUN T T, WENG X D, et al. The investigation of glucose metabolism and insulin secretion in subjects of chronic hepatitis B with cirrhosis[J]. Int J Clin Exp Pathol, 2015, 8(10): 13381-13386. |
19 | 刘丽, 江颖仪, 刘景. 不同Child-Pugh分级慢性乙型肝炎肝硬化患者糖代谢、胰岛素分泌情况及其与炎症反应的相关性分析[J]. 临床肝胆病杂志, 2020, 36(2): 324-328. |
LIU L, JIANG Y Y, LIU J.Glucose metabolism and insulin secretion in patients with chronic hepatitis B cirrhosis of different Child-Pugh grades and their association with inflammatory response[J].Journal of Clinical Hepatobiliary Disease, 2020, 36(2): 324-328. | |
20 | ALSEBAEY A, ELHELBAWY M. Insulin resistance is not a risk factor for oesophageal varices development in hepatitis C[J]. Trop Doct, 2019, 49(4): 281-285. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 684
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 424
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||